Celgene (CELG): Possible Deal For EngMab - Jefferies

September 16, 2016 7:21 AM EDT
Get Alerts CELG Hot Sheet
Price: $117.63 --0%

Rating Summary:
    28 Buy, 8 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 26 | Down: 14 | New: 13
Trade CELG Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Celgene (NASDAQ: CELG) and believes that there is evidence CELG is pursuing a deal (acquisition or partnership) w/ a pvt co, EngMab--whose bispecifics could provide an off-the-shelf, more broadly-applicable modality to hit BCMA (vs. CAR-T) and enable CELG to enter the emerging MM Ab space after having been late to the game on CD38s.

The analyst believes CELG’s high sustainable growth, driven by a strong base business, deep pipeline, and proactive BD, is underappreciated. No change to the price target of $137.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $107.35 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Jefferies & Co, Definitive Agreement

Add Your Comment